- Home
- SXTP vs JAGX Comparison
SXTP vs JAGX Comparison
Compare SXTP & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- JAGX
- Stock Information
- Founded
- SXTP 2010
- JAGX 2013
- Country
- SXTP United States
- JAGX United States
- Employees
- SXTP N/A
- JAGX N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- JAGX Health Care
- Exchange
- SXTP Nasdaq
- JAGX Nasdaq
- Market Cap
- SXTP 3.4M
- JAGX 3.4M
- IPO Year
- SXTP 2023
- JAGX N/A
- Fundamental
- Price
- SXTP $1.27
- JAGX $1.80
- Analyst Decision
- SXTP Buy
- JAGX Strong Buy
- Analyst Count
- SXTP 2
- JAGX 1
- Target Price
- SXTP $7.00
- JAGX $60.00
- AVG Volume (30 Days)
- SXTP 110.3K
- JAGX 96.8K
- Earning Date
- SXTP 08-13-2025
- JAGX 08-14-2025
- Dividend Yield
- SXTP N/A
- JAGX N/A
- EPS Growth
- SXTP N/A
- JAGX N/A
- EPS
- SXTP N/A
- JAGX N/A
- Revenue
- SXTP $984,494.00
- JAGX $11,810,000.00
- Revenue This Year
- SXTP $81.41
- JAGX $22.41
- Revenue Next Year
- SXTP $95.63
- JAGX $30.00
- P/E Ratio
- SXTP N/A
- JAGX N/A
- Revenue Growth
- SXTP 128.70
- JAGX 15.96
- 52 Week Low
- SXTP $1.24
- JAGX $1.78
- 52 Week High
- SXTP $12.70
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- SXTP 33.70
- JAGX 33.66
- Support Level
- SXTP $1.24
- JAGX $2.02
- Resistance Level
- SXTP $1.35
- JAGX $2.65
- Average True Range (ATR)
- SXTP 0.07
- JAGX 0.18
- MACD
- SXTP 0.03
- JAGX -0.00
- Stochastic Oscillator
- SXTP 15.38
- JAGX 2.30
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.